NEW YORK – The American College of Medical Genetics and Genomics said today that all breast cancer patients should be evaluated to determine if they should receive germline genetic testing for assessing their inherited risk for the disease.
However, the medical genetics professional organization doesn't recommend testing all breast cancer patients for germline pathogenic or likely pathogenic variants in BRCA1, BRCA2, and other breast cancer-linked genes.